| 1.0E-6 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0 | 1-year : | 0 |
| Resists | First : | 0 | Second : | 0 |
| Pivot price | 0 | |||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 | MA(20) : | 0 |
| MA(100) : | 0  |
MA(250) : | 0.01 |
|
| MACD | MACD : | -0.01  |
Signal : | -0.01 |
| %K %D | K(14,3) : | 0 | D(3) : | 1 |
| RSI | RSI(14): 28.51 | |||
| 52-week | High : | 0.05 | Low : | 0 |
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Wed, 11 Mar 2020
Mid-Afternoon Market Update: Dow Plunges Over 1300 Points As WHO Declares COVID-19 A Pandemic - Avid Bios - Benzinga
Thu, 14 Mar 2019
The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering - Yahoo! Voices
Mon, 27 Mar 2017
Sophiris Bio Reports Fourth Quarter And Full Year 2016 Financial Results And Key Corporate Highlights - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 1,370 (K) |
| Shares Short P.Month | 1,510 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | -0.11 |
| EPS Est This Year | -0.32 |
| EPS Est Next Year | -0.5 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -56.39 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | 0.09 |
| PEG Ratio | 0 |
| Price to Book value | -0.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|